结直肠癌靶向药物耐药机制研究进展  

Research progress on targeted drug resistance mechanisms against colorectal cancer

作　　者：刘明顺 方明治[1] 李敏[1] LIU Mingshun;FANG Mingzhi;LI Min(Department of Oncology,Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Jiangsu Nanjing 210000,China)

机构地区：[1]南京中医药大学附属南京中医院肿瘤科,江苏南京210000

出　　处：《现代肿瘤医学》2021年第15期2730-2735,共6页Journal of Modern Oncology

基　　金：江苏省南京市医学科技发展项目(编号:YKK15122);江苏省南京市卫生青年人才项目(编号:QRX17187)。

摘　　要：结直肠癌临床高发,并且近年来结直肠癌的发病率和病死率逐渐上升。晚期结直肠癌的治疗中靶向治疗占有重要地位,而靶向药物出现耐药是结直肠癌治疗失败的主要原因。靶向药物耐药机制复杂,RAS、RAF突变等经典机制已被熟知,但具体机制尚未完全明确,因此研究其耐药机制以及如何阻断耐药是当下重点研究方向。本文主要综述几种靶向治疗药物在结直肠癌治疗中的耐药机制研究进展。Colorectal cancer has a high clinical incidence.The incidence and mortality of colorectal cancer have gradually increased in recent years.Targeted therapy plays an important role in the treatment of advanced colorectal cancer,and resistance of targeted drugs is the main reason for the failure of colorectal cancer.Targeted drug resistance mechanisms are complex.Classical mechanisms such as RAS and RAF mutations have been known,but the specific mechanisms is still not fully clarified.Therefore,research on their drug resistance mechanisms and how to block drug resistance is still current the focus of research.This article mainly reviews the research progress on the drug resistance mechanism of several targeted therapeutic drugs in CRC treatment.

关 键 词：结直肠癌 靶向治疗 耐药 

分 类 号：R735.34[医药卫生—肿瘤]